GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia

This study will evaluate GN001 in adults aged 18 to 75 years with CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. GN001 is an investigational lentiviral vector-based treatment designed to generate CD19-targeted chimeric antigen receptor (CAR) T cells within the body. The main purpose is to assess safety and tolerability at different doses. The study will also assess antitumor activity, the expansion and persistence of CAR T cells, and biological responses to treatment. Participants will receive GN001 by intravenous infusion. The study i

Trial Details

NCT ID
NCT07910708
Phase
PHASE1
Sponsor
Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital
Status
RECRUITING
Cancer Type
Burkitt Lymphoma Lymphoma
Interventions
  • GN001
Locations (sample)
  • Kunming, Yunnan, China|25.03889,102.71833
  • Pu'er, Yunnan, China|22.78863,100.97481

Key Eligibility Criteria

  • Aged 18 to 75 years
  • CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia
  • Adequate organ function
  • Signed informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Burkitt Lymphoma Lymphoma Trials on Trialify →